Products&Pipeline
CT IDBrief Title
NCT05104125

Study to Evaluate the Safety and Efficacy of  ASC40 in Subjects With Moderate to Severe Acne Vulgaris

NCT05118776

Study to   Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With   Bevacizumab in Subjects With rGBM

NCT05107778

Study   to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a   in Subjects With HBV

NCT05118360

Study to  Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASH

NCT05118516

Safety,  Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet  in Healthy Subjects

NCT04965337

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

NCT04843449

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

NCT04845646

DDI Study of ASC41 Tablets in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

NCT04527250

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects                                                                                                                  

NCT04465890

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

NCT04352361

Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects

NCT04358523

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

NCT04686994

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

NCT04692025

Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy Volunteers

NCT04547894

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects                                                                                                                    

NCT04679129

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

NCT03430830

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

NCT03288636

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China            

NCT03362814

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

NCT03020134

Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China

NCT03020082

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

NCT03020095

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

NCT03019991

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China


For more information, please visithttps://www.clinicaltrials.gov/